Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?Marijn M. Speeckaert, Wim Van Biesen, J. Delanghe et al.|Nephrology Dialysis Transplantation|2014Cited by 115
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J.L. Heerspink, Bi‐Cheng Liu, Rajiv Agarwal et al.|Nephrology Dialysis Transplantation|2024Cited by 83
Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney DiseaseMieke Steenbeke, Griet Glorieux, Sophie Valkenburg et al.|Toxins|2021Cited by 32
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular DiseasesBrendon L. Neuen, Gina Campestri, V Perkovic et al.|JAMA|2026Cited by 5
Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman SyndromeMichiel L. A. J. Wieërs, Peter J. Conlon, Elisabeth A. M. Cornelissen et al.|Kidney International Reports|2025Cited by 4